Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment. Summary of Treatment Approach to Patients with Lung Cancer Harrison’s Principle of Internal Medicine 17 th Edition p558.

Similar presentations


Presentation on theme: "Treatment. Summary of Treatment Approach to Patients with Lung Cancer Harrison’s Principle of Internal Medicine 17 th Edition p558."— Presentation transcript:

1 Treatment

2 Summary of Treatment Approach to Patients with Lung Cancer Harrison’s Principle of Internal Medicine 17 th Edition p558

3 Non-small cell lung cancer NSCLC Stages I and II Surgery – Treatment of choice pulmonary resection – 5 year survival rate N0: 60-80%; N1: 50% – Lobectomy superior too wedge resection reducing local recurrence – Pneumonectomy: multiple lobes, very central tumors, patients with excellent pulmonary reserves – Wedge resection and segmentectomy (VATS): poor pulmonary reserve and small peripheral lesions

4 Non-small cell lung cancer NSCLC Stages I and II Radiotherapy with curative intent – Refuse surgery or not candidates for surgery Extent of disease and volume of chest for irradiation Distant metastases, malignant pleural effusion, cardiac involvement – Long term survival: 20% – Potentially curative, increase quality and length of life by controlling primary tumor and preventing symptoms related to recurrence – Treatment for curative intent: Gy – Palliative thoracic radiation Gy

5 Non-small cell lung cancer NSCLC Stages I and II Adjuvant Chemotherapy for NSCLC Stages IB and II – Improvement of 5% at 5 years with cispaltin-based adjuvant therapy – No role for stage IB disease Adjuvant Radiotherapy for NSCLC Stages I-II – Does not improve survival, may actually be detrimental to survival in N0 and N1 disease

6 Non-small cell lung cancer NSCLC with T3, N0 disease (Stage IIB) With peripheral chest wal invasion: resection of involved ribs and underlying lung Repaired with chest wall musculature or Marlex mesh and methymethacrylate 5 year survival rate: 35-50% Adjuvant chemotherapy recommended

7 Non-small cell lung cancer NSCLC Stage III Local therapy (surgery or radiation therapy) + systemic chemotherapy Non-small cell lung cancer NSCLC Stage IIIA Nonbulky IIIA Adjuvant chemotherapy

8 Non-small cell lung cancer NSCLC Stage IIIA Bulky IIIA – No evidence suggests that patients with bulky multilevel ipsilateral mediastinal lymph nodes (N2) have improved survival with surgery and either pre-or postoperative chemotherapy compared to treatment with chemotherapy plus radiotherapy. Treatment-related mortality greater in the surgery arm Surgery only conducted with clearing of mediastinal lymph nodes by neoadjuvant chemotherapy T4,N0 pr T4, N1 (Stage IIIB): preoperative chemotherapy

9 Non-small cell lung cancer NSCLC Stage IIIA Bulky NSCLC Stage IIIA and Dry IIIB (IIIB without a Pleural Effusion) – Chemotherapy + radiation therapy: treatment of choice Improvement in median and long-term survival Concurrently > sequential

10 Disseminated NSCLC Palliative Radiation Therapy To relieve urgent severe symptoms such as bronchial obstruction with pneumonitis, hemoptysis, upper airway or SVC obstruction, brain or spinal cord compression, or painful bony mets Brain mets, spinal cord compression, symptomatic masses and bone lesions

11 Disseminated NSCLC Chemotherapy Palliates symptoms, improves quality of life, improves survival in newly diagnosed patients with stage IV NSCLC Cost-effective palliation for stage IV NSCLC For previously untreated, good-performance status patients: – chemotherapy consisting of two drugs (“doublets”): Cisplatin/ carboplatin Taxane (paclitaxel/ docetaxel), gemcitabine or a vinca alkaloid

12 Disseminated NSCLC VEGF Targeted Therapy Bevacizumab Improves response rate, progression-free survival and overall survival of patients with advanced disease when combined with chemotherapy SE: bleeding, hypertension and proteinuria

13 Disseminated NSCLC EGFR Targeted Therapy Erlotinib 2 nd or 3 rd line therapy for NSCLC For patients whose tumors respond to EGFR TKI therapy

14 Small Cell Lung Cancer Chemotherapy Etoposide + Cisplatin/ carboplatin – Most widely used – given every 3 weeks outpatient basis for 4-6 cycles

15 Small Cell Lung Cancer Limited-Stage Disease Combined-Modality Chemoradiotherapy More effective than sequential chemoradiation More esophagitis and hematologic toxicity Palliative Radiation Therapy Cranial radiation decreases the signs and symptoms of brain metastases Surgery Not routinely recommended High cure rates if postoperative chemotherapy is used

16 Lung Cancer Prevention Encourage smoking cessation Chemoprevention – No benefit has yet been shown – Vitamin E and β-carotene Actually increased the risk of lung cancer in heavy smokers


Download ppt "Treatment. Summary of Treatment Approach to Patients with Lung Cancer Harrison’s Principle of Internal Medicine 17 th Edition p558."

Similar presentations


Ads by Google